Asymmetric Septal Hypertrophy (ASH) refers to a medical condition characterized by the abnormal thickening of the interventricular septum, the partition between the left and right ventricles of the heart. This condition is also known as asymmetrical septal thickening or idiopathic hypertrophic subaortic stenosis (IHSS). ASH is typically classified as a form of hypertrophic cardiomyopathy (HCM), a disease in which the heart muscle becomes thickened, resulting in challenges for the heart to pump blood efficiently.
In cases of ASH, the thickening of the septum is asymmetrical, meaning that it occurs more prominently on one side, rather than uniformly. This can cause structural and functional abnormalities within the heart, potentially leading to various symptoms, such as shortness of breath, chest pain, dizziness, and fainting. ASH can also narrow the left ventricular outflow tract, obstructing the flow of blood from the left ventricle to the aorta.
The precise cause of ASH is not yet fully understood, and it may be either inherited or acquired. Some genetic mutations have been identified as potential contributors to the condition. However, the majority of cases are considered idiopathic, meaning no specific cause can be determined.
Treatment options for ASH aim to alleviate symptoms and prevent complications. Medications may be prescribed to regulate heart function and manage symptoms. In severe cases, surgical interventions like septal myectomy or alcohol septal ablation may be necessary to reduce the septal thickening and improve blood flow. Regular monitoring and ongoing care from a cardiologist are typically recommended for individuals with ASH.
